Kiniksa Pharmaceuticals International (KNSA) Consolidated Net Income (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Consolidated Net Income came in at $25.4 million in Q2 2026, up 42.62% YoY from $17.8 million in Q2 2025, and up 12.57% on a QoQ basis from $22.6 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Consolidated Net Income (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Consolidated Net Income data on file, last reported at $25.4 million in Q2 2026.
- Quarterly Consolidated Net Income rose 42.62% year-over-year to $25.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $80.7 million (up 1583.88% YoY) and the FY2025 annual result came in at $59.0 million, up 236.61% from the prior year.
- Consolidated Net Income advanced to $25.4 million in Q2 2026, from $22.6 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $224.1 million in Q3 2022 to a low of -$49.2 million in Q4 2023.
- A 5-year average of $15.0 million and a median of $2.3 million in 2024 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income soared 833.67% — and 2023, when it tumbled 155.63%.
- Tracing KNSA's Consolidated Net Income over 5 years: stood at $88.5 million in 2022, then slumped by 155.63% to -$49.2 million in 2023, then jumped by 81.95% to -$8.9 million in 2024, then soared by 259.75% to $14.2 million in 2025, then surged by 79.11% to $25.4 million in 2026.
- The last three Consolidated Net Income figures came in at $25.4 million (Q2 2026), $22.6 million (Q1 2026), and $14.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.56 Bn | 220.03 Mn | 25.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.43 Mn |
| Mar 31, 2026 | 22.59 Mn |
| Dec 31, 2025 | 14.20 Mn |
| Sep 30, 2025 | 18.44 Mn |
| Jun 30, 2025 | 17.83 Mn |
| Mar 31, 2025 | 8.54 Mn |
| Dec 31, 2024 | -8.89 Mn |
| Sep 30, 2024 | -12.69 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | -17.70 Mn |
| Dec 31, 2023 | -49.24 Mn |
| Sep 30, 2023 | -13.86 Mn |
| Jun 30, 2023 | 14.97 Mn |
| Mar 31, 2023 | -12.27 Mn |
| Dec 31, 2022 | 88.53 Mn |
| Sep 30, 2022 | 224.09 Mn |
| Jun 30, 2022 | -19.98 Mn |
| Mar 31, 2022 | -25.21 Mn |
| Dec 31, 2021 | -44.08 Mn |
| Sep 30, 2021 | -30.54 Mn |